Literature DB >> 15014824

[Study of resisting leukoplakia canceration and angiogenesis of Herba Erigerontis].

C T Zhou1, S L Zhang, L Hua, W J Zhong, Z G Jin, R Y Ding.   

Abstract

OBJECTIVE: To evaluate the effect of resisting canceration of Herba Erigerontis HEr and that of angiogenesis; seek the mechanism of angiogenesis.
METHODS: 150 golden hamsters were randomly divided into model group (66 animals), HEr group (66) and control group (18). Carcinomatous conversions of golden hamster cheek pouches induced by Sally way and interrupted by Herba Erigerontis. Ink perfusion, analysis of images, resin cast form of micro vessel, alpha-SMA detection and histopathological examination were applied to observe their changing patterns.
RESULTS: The rate of leukoplakia canceration of Herba Erigerontis group was 50% lower than that of model group. The rate of normal cells was about four times more than that of model. alpha-SMA of Herba Erigerontis 65.76 was higher than that of model (P<0.001). There was no significant difference between angeion vessel area and density (P>0.05). Nevertheless, the resin cast form of micro-vessel showed that its configuration and spacious arrangement was similar to control group.
CONCLUSION: Herba Erigerontis has the function of preventing leukoplakia canceration absolutely. Maybe its mechanism is to upregulate the expression of alpha-SMA. It has no obvious effect of angio-hyperplasia and expansion in the course of leukoplakia canceration. However, it has the protecting function to angio-configuration and spacious arrangement and the integrity of angeion vessed wall. Probably its mechanism is promoting blood circulation by removing blood stasis and benign angiogenesis so as to resist canceration.

Entities:  

Year:  2000        PMID: 15014824

Source DB:  PubMed          Journal:  Shanghai Kou Qiang Yi Xue        ISSN: 1006-7248


  1 in total

1.  Genome-wide identification and expression profile of the MADS-box gene family in Erigeron breviscapus.

Authors:  Wen Tang; Yayi Tu; Xiaojie Cheng; Lili Zhang; Hengling Meng; Xin Zhao; Wei Zhang; Bin He
Journal:  PLoS One       Date:  2019-12-20       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.